Opinion|Videos|December 5, 2024
Treatment Switches and the Future of Hidradenitis Suppurativa Management
Author(s)Jennifer Hsiao, MD, Rani Cooper, MD
Panelists discuss how identifying optimal timing for treatment switches and emerging therapeutic innovations are reshaping the management landscape for hidradenitis suppurativa, with the potential to improve long-term patient outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
4
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
5